Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1042-1051

  Phetsuksiri, Benjawan ^a   Baulard, Alain R ^a   Cooper, Andrea M ^a   Minnikin, David E ^b   Douglas, James D ^b   Besra, Gurdyal S ^a   Brennan, Patrick J ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHIONAMIDE; ISONIAZID; MYCOLIC ACID; TIOCARLIDE;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SELECTIVITY; FATTY ACID SYNTHESIS; GEOGRAPHIC DISTRIBUTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM; MYCOBACTERIUM AURUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

EID: 0032930265     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1042     Document Type: Article

References (52)

1. Banerjee, A., E. Dubnau, A. Quemard, V. Balasubramanian, K. S. Um, T. Wilson, D. Collins, G. DeLisle, and W. R. Jacobs, Jr. 1994. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230.
2. Barnes, P., A. B. Bloch, P. T. Davidson, and D. E. Snider, Jr. 1991. Tuberculosis in patients with immunodeficiency virus infection. N. Engl. J. Med. 324:1644-1650.
3. Bernstein, J., W. A. Lott, B. A. Steinberg, and H. L. Yale. 1952. Chemotherapy of experimental tuberculosis: isonicotinic acid hydrazide (Nydrazid) and related compounds. Annu. Rev. Tuberc. 65:357-364.
4. Bloch, K. 1975. Fatty acid synthetase from Mycobacterium phlei. Methods Enzymol. 35:84-90.
5. Bloch, K. 1977. Control mechanisms for fatty acid synthesis in Mycobacterium smegmatis. Adv. Enzymol. 45:1-84.
6. Bloom, B. R., and C. J. L. Murray. 1992. Tuberculosis; commentary on a reemergent killer. Science 257:1055-1064.
7. Cohn, M. L., R. F. Waggoner, and J. K. McClatchy. 1968. The 7H11 media for the cultivation of mycobacteria. Am. Rev. Respir. Dis. 98:295-296.
8. Combs, D. L., R. J. O'Brien, and L. J. Geiter. 1990. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability: the report of final results. Ann. Intern. Med. 112:397-406.
9. Dooley, S. W., W. R. Jarvis, W. J. Martone, and D. E. Snider, Jr. 1992. Multidrug-resistant tuberculosis. Ann. Intern. Med. 117:257-259.
10. Heifets, L. B. 1991. Drug susceptibility tests in management of chemotherapy, p. 99-101. In L. B. Heifets (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Inc., Boca Raton, Fla.
11. Heifets, L. B. 1991. General concepts in the testing drug susceptibility, p. 2-11. In L. B. Heifets (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Inc., Boca Raton, Fla.
12. Jackowski, S., J. E. Croman, Jr., and C. O. Rock. 1991. Lipid metabolism in prokaryote, p. 43-85. In D. E. Vance and J. Vance (ed.), Biochemistry of lipids, lipoproteins and membranes. Elsevier Science Publishers B.V., Amsterdam, The Netherlands.
13. Johnson, K., and P. G. Schultz. 1994. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J. Am. Chem. Soc. 116:7425-7426.
14. Kampelmann, F. 1970. Results of monotherapy with isoxyl in untreated pulmonary tuberculosis cases of different difficulties and isoxyl in routine therapy. Antibiot. Chemother. 26:96-104.
15. Kolattukudy, P. E., N. D. Fernandes, A. K. Azad, A. M. Fitzmaurice, and T. D. Sirakova. 1997. Biochemistry and molecular genetics of cell-wall lipid biogenesis in mycobacteria. Mol. Microbiol. 24:263-270.
16. Magnuson, K., S. Jackowski, C. O. Rock, and J. E. Croman, Jr. 1993. Regulation of fatty acid biosynthesis in Escherichia coli. Microbiol. Rev. 57:522-524.
17. McClatchy, J. K. 1986. Antimycobacterial drugs: mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids, p. 181-222. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md.
18. Mdluli, K., D. R. Sherman, M. J. Hickey, B. N. Kreiswirth, S. Morris, C. K. Stover, and C. E. Barry. 1996. Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J. Infect. Dis. 174:1085-1090.
19. Mdluli, K., R. A. Slayden, Y. Zhu, S. Ramaswamy, X. Pan, D. Mead, D. D. Crane, J. M. Musser, and C. E. Barry III. 1998. Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science 280:1607-1610.
20. Middlebrook, K. 1952. Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. Am. Rev. Tuberc. 64:765-767.
21. Minnikin, D. E., S. M. Minnikin, J. H. Parlett, M. Goodfellow, and M. Magnusson. 1984. Mycolic acid patterns of some species of Mycobacterium. Arch. Microbiol. 139:225-231.
22. Murray, C. J. L., K. Styblo, and A. Rouillon. 1990. Disease control priorities in developing countries: burden, intervention and cost. Bull. Int. Union Tuberc. Lung Dis. 65:6-24.
23. Noto, T., S. Miyakawa, H. Oishi, H. Endo, and H. Okazaki. 1982. Thiolactomycin, a new antibiotic. III. In vitro antibiotic activity. J. Antibiot. (Tokyo) 35:401-410.
24. Ordway, D. J., M. G. Sonnenberg, S. A. Donahue, J. T. Belisle, and I. M. Orme. 1995. Drug-resistant strains of Mycobacterium tuberculosis exhibit a wide range of virulence for mice. Infect. Immun. 63:741-743.
25. Quemard, A., C. Lacave, and G. Laneelle. 1991. Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum. Antimicrob. Agents Chemother. 35:1035-1039.
26. Quemard, A., G. Laneelle, and C. Lacave. 1992. Mycolic acid synthesis: a target for ethionamide in mycobacteria? Antimicrob. Agents Chemother. 36:1316-1321.
27. Quemard, A., J. C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, W. R. Jacobs, Jr., and J. S. Blanchard. 1995. Enzymatic characterization of the target of isoniazid in Mycobacterium tuberculosis. Biochemistry 34:8235-8241.
28. Ratledge, C. R. 1982. Lipids: cell composition, fatty acid biosyntheses, p. 53-94. In C. Ratledge and J. Standford (ed.), The biology of mycobacteria. Academic Press, San Diego, Calif.
29. Rhoades, E. R., and I. M. Orme. 1997. Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect. Immun. 65:1189-1195.
30. Rist, N. 1960. L'activitté antituberculeuse de l'ethionamide. Adv. Tuberc. Res. 10:69-126.
31. Rozwarski, D. A., G. A. Grant, D. H. R. Barton, W. R. Jacobs, Jr., and J. C. Sacchettini. 1998. Modification of the NADH of the isoniazid target (inhA) from Mycobacterium tuberculosis. Science 279:98-102.
32. Sacchettini, J. C., and J. S. Blanchard. 1996. The structure and function of isoniazid target in M. tuberculosis. Res. Microbiol. 147:36-43.
33. Schmid, P. C. H. 1970. Clinical experiences in cases of primary tuberculosis with tuberculostaticum isoxyl. Antibiot. Chemother. 16:108-116.
34. Shoeb, H. A., B. U. Bowman, Jr., A. C. Ottolenghi, and A. J. Merola. 1985. Peroxidase-mediated oxidation of isoniazid. Antimicrob. Agents Chemother. 27:399-403.
35. Slayden, R. A., R. E. Lee, J. W. Armour, A. M. Cooper, I. M. Orme, P. J. Brennan, and G. S. Besra. 1996. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis in mycobacteria. Antimicrob. Agents Chemother. 40:2813-2819.
36. Snider, D. E., Jr., M. Raviglione, and A. Kochi. 1994. Global burden of tuberculosis, p. 2-11. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control, American Society for Microbiology, Washington, D.C.
37. Snider, D. E., Jr., and W. L. Roper. 1992. The new tuberculosis. N. Engl. J. Med. 326:703-705.
38. Stone, M. S., R. J. Wallace, Jr., J. M. Swenson, C. Thornsberry, and L. A. Christensen. 1983. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotic. Antimicrob. Agents Chemother. 24:486-493.
39. Takayama, K. 1974. Selective action of isoniazid on the synthesis of cell wall mycolates in mycobacteria. Ann. N.Y. Acad. Sci. 235:426-438.
40. Takayama, K., H. K. Schnoes, E. L. Armstrong, and R. W. Boyle. 1975. Site of inhibitory action of isoniazid in the synthesis of mycolic aids in Mycobacterium tuberculosis. J. Lipid Res. 16:308-317.
41. Takayama, K. L., L. Wang, and H. L. David. 1972. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2:29-35.
42. Titscher, R. 1966. Monotherapie mit isoxyl/DAT bei tuberculose-asylierungsfallen. Prax. Pneumol. 20:202.
43. Urbancik, B. 1966. A clinical trial of thiocarlide (isoxyl). Tubercle 47:283-288.
44. Urbancik, B. 1970. Clinical experiences with thiocarlide (isoxyl). Antibiot. Chemother. 16:117-123.
45. Wang, L., and K. Takayama. 1972. Relation between the uptake of isoniazid and its action on in vivo mycolic acid synthesis in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2:438-441.
46. Winder, F. G. 1960. Catalase and peroxidase in mycobacteria. Am. Rev. Respir. Dis. 81:68-78.
47. Winder, F. G. 1982. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of mycobacteria, p. 353-438. In C. Ratledge and J. Standford (ed.), The biology of mycobacteria, vol. 1. Academic Press, Inc., New York, N.Y.
48. Winder, F. G., and P. B. Collins. 1970. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J. Gen. Microbiol. 63:41-48.
49. Winder, F. G., P. B. Collins, and D. Whelan. 1971. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. J. Gen. Microbiol. 66:379-380.
50. Yamamoto, T., R. Amitani, K. Suzuki, T. Tanaka, T. Murayama, and F. Kuze. 1996. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:426-428.
51. Youatt, J. 1969. A review of the action of isoniazid. Am. Rev. Respir. Dis. 99:729-749.
52. Zhang, Y., B. Heym, B. Allen, D. Young, and S. Cole. 1992. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-593.